The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers. The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine (JNJ-78436725) can prevent symptomatic COVID-19 after a single dose regimen. Up to 60,000 volunteers will be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.
The Janssen Pharmaceutical Companies of Johnson & Johnson developed the investigational vaccine (also known as Ad.26.COV2.S) and is leading the clinical trial as regulatory sponsor. Janssen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, are funding the trial.
"Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified. This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry and academia," said NIAID Director Anthony S. Fauci, M.D. "It is likely that multiple COVID-19 vaccine regimens will be required to meet the global need. The Janssen candidate has showed promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose."
The Phase 3 trial is being conducted in collaboration with Operation Warp Speed(link is external) (OWS), a multi-agency collaboration overseen by HHS and the Department of Defense that aims to accelerate the development, manufacturing and distribution of medical countermeasures for COVID-19. OWS and CoVPN also are assisting with additional COVID-19 preventive candidate vaccines, including mRNA-1273, an investigational vaccine co-developed by NIAID and the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and AZD1222, a vaccine candidate being developed by United Kingdom-based biopharmaceutical company AstraZeneca.
Adults who are interested in joining this study can visit Coronaviruspreventionnetwork.org(link is external) or ClinicalTrials.gov and search identifier NCT04505722.
by ARGeezer - Oct 24 23 comments
by Frank Schnittger - Oct 23 69 comments
by ARGeezer - Oct 22 5 comments
by ATinNM - Oct 19 54 comments
by Frank Schnittger - Oct 19 123 comments
by Frank Schnittger - Oct 11 38 comments
by Frank Schnittger - Oct 8 126 comments
by Frank Schnittger - Oct 6 167 comments
by ARGeezer - Oct 2423 comments
by Frank Schnittger - Oct 2369 comments
by ARGeezer - Oct 225 comments
by ATinNM - Oct 1954 comments
by Frank Schnittger - Oct 19123 comments
by gmoke - Oct 15
by Frank Schnittger - Oct 1138 comments
by Frank Schnittger - Oct 8126 comments
by Frank Schnittger - Oct 6167 comments
by Frank Schnittger - Oct 135 comments
by IdiotSavant - Sep 286 comments